HOME         WEBSITE         SUBSCRIBE           E-GREETINGS   
                               

Monday, March 15, 2010

Financial News Flash

Nuclear Bill Stalls in India, Delaying Entry of GE-Hitachi, Westinghouse India’s government failed to introduce a bill intended to shield U.S. nuclear equipment suppliers from liability, delaying the entry of companies including General Electric Co.’s atomic venture. 

Most Indian Stocks Decline as Inflation Accelerates; State Bank Retreats Most Indian stocks fell led by banks after a report showed inflation accelerated more than economists expected. State Bank of India led the drop. 

India Inflation Accelerates to 16-Month High in February on Factory Prices India’s inflation accelerated to a 16-month high in February, increasing pressure on the central bank to raise interest rates from a record low.

Facebook to Start First India Center to Help Support Operations Globally Facebook Inc., the owner of the largest social networking site, plans to set up its first Indian center at Hyderabad to support its growing global operations. 

Standard Chartered Seeking Indian, South Korean Equity Hires for Expansion Standard Chartered Plc, the U.K. bank that makes most of its profit in emerging markets, will hire stock analysts and traders in India and South Korea to expand its operations in Asia. 

NTPC Plans 2010-11 Coal Imports of 14 Million Tons, Chairman Sharma Says NTPC Ltd., India’s biggest electricity generator, plans to import 14 million metric tons of coal in the year starting April 1, Chairman R.S. Sharma said. 

Posco Starts Building Galvanized Steel Sheet Plant in India for Automakers Posco, South Korea’s largest steelmaker, began building a $240 million plant in India to produce galvanized steel sheet to supply automakers. 

Hindustan Construction to Buy Controlling Stake in Developer Karl Steiner Hindustan Construction Co. will buy a controlling stake in Karl Steiner AG and purchase remaining shares in the Swiss developer in 2014, the Indian company said in a statement to the Bombay Stock Exchange today. 

Tata Motors Group February Global Sales Rise 59% Helped by Jaguar Demand Tata Motors Ltd. posted a 59 percent increase in group global sales in February, helped by a surge in demand at the Jaguar Land Rover luxury unit. 

Indian 10-Year Bond Yields Hold Near 17-Month High Before Inflation Data India’s 10-year bond yields held near the highest in almost 17 months as investors refrained from buying on concern accelerating inflation will erode the value of debt returns. 

Stocks in U.S. Fall on Concern Over Dodd Financial Rules, China's Economy U.S. stocks fell for a second day amid growing concern lawmakers will limit trading at banks and speculation that China will restrict economic growth to curb inflation. 

EU Finance Ministers Spar Over Aid for Greece, Bet Bailout Won't Be Needed European finance ministers sparred over an aid package for debt-ridden Greece, banking on the Greek government’s budget cuts to make a bailout unnecessary. 

Commercial Mortgage Debt Rallies as TALF Draws to a Close: Credit Markets Commercial mortgage-backed bond returns are accelerating as the Federal Reserve ends support for the $700 billion market, showing growing confidence that loan defaults won’t derail the economic recovery. 

Phillips-Van Heusen Agrees to Buy Tommy Hilfiger From Apax for $3 Billion Phillips-Van Heusen Corp. agreed to buy clothing maker Tommy Hilfiger BV from private-equity firm Apax Partners LP for 2.2 billion euros ($3 billion), adding the brand to its Calvin Klein and Izod lines. Phillips-Van Heusen shares jumped in New York trading. 

Munich Re, Berkshire Among Reinsurers With Gains in Policyholders' Surplus Munich Re and Warren Buffett’s Berkshire Hathaway Inc. are among reinsurers reporting a third straight quarterly increase in policyholders’ surplus as capital markets improve and earnings rise. 

OSI Chief Rejects Astellas Bid as Overlooking Tarceva's $7 Billion Promise OSI Pharmaceuticals Inc. Chief Executive Officer Colin Goddard said Astellas Pharma Inc.’s $3.5 billion hostile takeover bid doesn’t reflect peak annual revenue of $7 billion from the cancer pill Tarceva. 

source: Bloomberg

Blog Archive

____________________________________________________________________________________________

Disclaimer - All investments in Mutual Funds and securities are subject to market risks and uncertainty of dividend distributions and the NAV of schemes may go up or down depending upon factors and forces affecting securities markets generally. The past performance of the schemes is not necessarily indicative of the future performance and may not necessarily provide a basis for comparison with other investments. Investors are advised to go through the respective offer documents before making any investment decisions. Prospective client(s) are advised to go through all comparable products in offer before taking any investment decisions. Mutual Funds and securities investments are subject to market risks and there is no assurance or guarantee that the objectives of the fund will be achieved. Information gathered & material used in this document is believed to be from reliable sources. Decisions based on the information provided on this newsletter/document are for your own account and risk.


In the preparation of the material contained in this document, Varun Vaid has used information that is publicly available, including information developed in-house. Some of the material used in the document may have been obtained from members/persons other than the Varun Vaid and which may have been made available to Varun Vaid. Information gathered & material used in this document is believed to be from reliable sources. Varun Vaid however does not warrant the accuracy, reasonableness and/or completeness of any information. For data reference to any third party in this material no such party will assume any liability for the same. Varun Vaid does not in any way through this material solicit any offer for purchase, sale or any financial transaction/commodities/products of any financial instrument dealt in this material. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice.


Varun Vaid, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. All recipients of this material should before dealing and/or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. Any person subscribing to or investigating in any product/financial instruments should do soon the basis of and after verifying the terms attached to such product/financial instrument. Financial products and instruments are subject to market risks and yields may fluctuate depending on various factors affecting capital/debt markets. Please note that past performance of the financial products and instruments does not necessarily indicate the future prospects and performance there of. Such past performance may or may not be sustained in future. Varun Vaid, including persons involved in the preparation or issuance of this material may; (a) from time to time, have long or short positions in, and buy or sell the securities mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation in the financial instruments/products/commodities discussed here in or act as advisor or lender / borrower in respect of such securities/financial instruments/products/commodities or have other potential conflict of interest with respect to any recommendation and related information and opinions. The said person may have acted upon and/or in a manner contradictory with the information contained here. No part of this material may be duplicated in whole or in part in any form and or redistributed without the prior written consent of Varun Vaid. This material is strictly confidential to the recipient and should not be reproduced or disseminated to anyone else.


Varun Vaid also does not take any responsibility for the contents of the advertisements published. Readers are advised to verify the contents on their own before acting there upon.


Published Credits goes to following sources & all the mentioned sources as footer below the published material- Bloomberg, Valueresearch Online, Capital Market, Navindia, Franklin Templeton, Kitco, SBI AMC, LIC AMC, JM Financial AMC, HDFC AMC, The Hindu, Business Line, Personal FN, Economic Times, Reuters, Outlook Money, Business Standard, Times of India etc.